- Sections
- C - Chimiemétallurgie
- C07D - Composés hétérocycliques
- C07D 231/18 - Un atome d'oxygène ou de soufre
Détention brevets de la classe C07D 231/18
Brevets de cette classe: 315
Historique des publications depuis 10 ans
|
18
|
23
|
17
|
38
|
27
|
21
|
11
|
11
|
13
|
10
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Inflazome Limited | 85 |
24 |
| Theravance Biopharma R&D IP, LLC | 456 |
14 |
| Bristol-myers Squibb Company | 4855 |
8 |
| The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth, Near Dublin | 165 |
8 |
| The University of Queensland | 664 |
8 |
| Novartis AG | 10725 |
7 |
| Arena Pharmaceuticals, Inc. | 363 |
7 |
| BASF SE | 20991 |
6 |
| Northwestern University | 3417 |
6 |
| Cardioxyl Pharmaceuticals, Inc. | 49 |
6 |
| VALO Health, Inc. | 175 |
6 |
| Bayer Pharma AG | 1054 |
5 |
| The Johns Hopkins University | 5714 |
5 |
| Nippon Soda Co., Ltd. | 895 |
5 |
| Abbott Laboratories | 2399 |
4 |
| Bayer AG | 3346 |
4 |
| Takeda Pharmaceutical Company Limited | 2706 |
4 |
| Merial, Inc. | 218 |
4 |
| Nissan Chemical Corporation | 2057 |
4 |
| Sumitomo Pharma Co., Ltd. | 583 |
4 |
| Autres propriétaires | 176 |